Cytokinetics (CYTK) Current Leases (2019 - 2026)

Cytokinetics (CYTK) has reported Current Leases for 8 consecutive years, with $21.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Leases rose 7.08% year-over-year to $21.0 million; the TTM figure through Mar 2026 stood at $21.0 million (up 7.08% YoY), while the FY2025 annual figure was $19.1 million, up 0.7% from the prior year.
• Current Leases improved to $21.0 million in Q1 2026 per CYTK's latest filing, from $19.1 million in the prior quarter.
• Across five years, Current Leases topped out at $21.0 million in Q1 2026 and bottomed at $12.8 million in Q4 2022.
• Historically, Current Leases has averaged $17.5 million across 5 years, with a median of $18.2 million in 2024.
• On a YoY basis, Current Leases climbed as much as 291.62% in 2022 and fell as far as 13.68% in 2022.
• Cytokinetics' Current Leases stood at $12.8 million in 2022, then soared by 39.46% to $17.9 million in 2023, then increased by 6.08% to $19.0 million in 2024, then increased by 0.7% to $19.1 million in 2025, then grew by 9.68% to $21.0 million in 2026.
• Business Quant data shows CYTK's Current Leases at $21.0 million in Q1 2026, $19.1 million in Q4 2025, and $20.6 million in Q3 2025.